ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2012
Lifetime costs of the top five cancers in Taiwan.
Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Lifetime direct healthcare costs of treating colorectal cancer: a systematic review.The European journal of health economics : HEPAC : health economics in prevention and care · 2023Pooled it
- Suicide Mortality Risk among Patients with Lung Cancer-A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2023Pooled it
- Cost of illness in colorectal cancer: an international review.PharmacoEconomics · 2013Pooled it
- Survivability prognosis of lung cancer patients with comorbidities-a Gaussian Bayesian network model.Medical & biological engineering & computing · 2025Article
- Direct and indirect medical costs of bladder cancer in Iran.Cost effectiveness and resource allocation : C/E · 2023Article
- Cost-Effectiveness Analysis from a Societal Perspective of Recurrence Index for Distant Recurrence (RecurIndex) in Women with Hormone Receptor-Positive and HER2-Negative Early-Stage Breast Cancer.Cancer management and research · 2022Article
- The Lifetime Cost Estimation of Human Papillomavirus-related Diseases in China: A Modeling Study.Journal of translational internal medicine · 2021Article
- Survivability Prognosis for Lung Cancer Patients at Different Severity Stages by a Risk Factor-Based Bayesian Network Modeling.Journal of medical systems · 2020Article
- Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians.PharmacoEconomics · 2020Review
- Direct and Indirect Costs Associated with Coronary Artery (Heart) Disease in Tabriz, Iran.Risk management and healthcare policy · 2020Article
- Economic burden of colorectal cancer in Iran in 2012.Medical journal of the Islamic Republic of Iran · 2017Article
- Article
- The Economic Burden of Breast Cancer in Iran.Iranian journal of public health · 2015Article
- Comparing the effectiveness of capecitabine versus 5-fluorouracil/leucovorin therapy for elderly Taiwanese stage III colorectal cancer patients based on quality-of-life measures (QLQ-C30 and QLQ-CR38) and a new cost assessment tool.Health and quality of life outcomes · 2015Article
- Estimation of benefit of prevention of occupational cancer for comparative risk assessment: methods and examples.Occupational and environmental medicine · 2012Article
- The role of human papillomavirus type 16 E6/E7 oncoproteins in cervical epithelial-mesenchymal transition and carcinogenesis.Oncology letters · 2012Article
- Cost-Utility Analysis of Trastuzumab-Emtansine Versus Trastuzumab for the Treatment of Residual Invasive HER-2-Positive Breast Cancer in Iran.Iranian journal of pharmaceutical research : IJPRArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this study was to determine cancer-related medical care costs for long-term cancer care costs of breast, cervical, liver, lung, and colorectal cancer. Data were sourced from Taipei Veterans General Hospital cancer registry and claim data during 1999-2002. Besides, claimed data from National Health Insurance were used to match the comparison group. To estimate lifetime cost (10 years), the whole disease process was divided into initial, continuing, and terminal three phases. The expected lifetime cost of a specific cancer patient was estimated by incorporating the average phase-specific costs with the survival rate and mortality rate. The undiscounted average lifetime costs (10 years) for lung cancer, colorectal cancer, liver cancer, cervical cancer, and breast cancer were NT$448,371 (1USD≒NTD 33), NT$584,985, NT$351,222, NT$511,563, and NT$674,282 (in 2002 NTD), respectively. The aggregate lifetime cost of cancer is useful for health policymaking and clinical decision-making.
Indexed as
Identifiers
21442437What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.